Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Blood (2019) 134 (Supplement_1): 1416.

https://doi.org/10.1182/blood-2019-127082

Published: 2019

Journal Articles

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Blood (2018) 132 (Supplement 1): 993.

https://doi.org/10.1182/blood-2018-99-111144

Published: 2018

Journal Articles

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Blood (2018) 132 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2018-99-110366

Published: 2018

Journal Articles

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Riwa Sakr, MD, Sylvain Pilorge, MD, Stephane De Botton, Claude Chahine, MD, Tereza Coman, MD PhD, Marcel Adler, MD, Jean-Baptiste Micol, MD PhD, Florence Pasquier, MD PhD, Christophe Willekens, MD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Eric Solary, MD, Vincent Ribbag, Jean-Henri Bourhis, Cristina Castilla-LLorente, MD PhD

Blood (2017) 130 (Supplement 1): 5544.

https://doi.org/10.1182/blood.V130.Suppl_1.5544.5544

Published: 2017

Journal Articles

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Raphael Itzykson, MD PhD, Nicolas Duployez, PharmD, PhD, Annette Fasan, PhD, Alice Marceau-Renaut, PharmD, Manja Meggendorfer, PhD, Eric Jourdan, MD, Arnaud Petit, MD PhD, Hélène Lapillonne, MD PhD, Jean-Baptiste Micol, MD PhD, Pascale Cornillet-Lefebvre, Norbert Ifrah, MD, Guy Leverger, MD PhD, Herve Dombret, MD, Nicolas Boissel, MD PhD, Torsten Haferlach, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 26.

https://doi.org/10.1182/blood.V130.Suppl_1.26.26

Published: 2017

Journal Articles

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Christophe Willekens, MD, Veronique Saada, Sophie Broutin, Julia Delahousse, Aline Renneville, MDPhD, Cynthia Petrovanu, Christophe Marzac, Jean-Baptiste Micol, MD PhD, Éric Solary, MD PhD, Florence Pasquier, MD PhD, Julien Lazarovici, MD, Vincent Ribrag, Claude Preudhomme, PharmD, PhD, Cyril Quivoron, Virginie Penard-Lacronique, PhD, Angelo Paci, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 1313.

https://doi.org/10.1182/blood.V130.Suppl_1.1313.1313

Published: 2017

Journal Articles

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

Blood (2017) 130 (Supplement 1): 473.

https://doi.org/10.1182/blood.V130.Suppl_1.473.473

Published: 2017

Journal Articles

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Khalil Saleh, MD, Christophe Willekens, MD, Jean Edouard Martin, Myriam Kossai, Nadine Khalifé-Saleh, MD, Véronique Saada, PharmD, Nathalie Auger, Alina Danu, MD, Julien Lazarovici, MD, Alexandra Leary, Suzette Delaloge, Jean Henri Bourhis, MD PhD, Éric Solary, MD PhD, Serge Koscielny, Stephane de Botton, Jean-Baptiste Micol, MD PhD

Blood (2016) 128 (22): 4006.

https://doi.org/10.1182/blood.V128.22.4006.4006

Published: 2016

Journal Articles

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Stanley Chun-Wei Lee, PhD, Khrystyna Dilai, Esther A. Obeng, MDPhD, Eunhee Kim, PhD, Jean-Baptiste Micol, MD PhD, Akihide Yoshimi, MD PhD, Christophe Willekens, MD, Daichi Inoue, Véronique Saada, PharmD, Hana Cho, Young Rock Chung, MS, James Palacino, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Peter Smith, Benjamin L. Ebert, MD PhD, Robert Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 961.

https://doi.org/10.1182/blood.V128.22.961.961

Published: 2016

Journal Articles

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Jean-Baptiste Micol, MD, Nicolas Duployez, Alessandro Pastore, MD, Robert Williams, Eunhee Kim, PhD, Stanley Lee, Benjamin Durham, MD PhD, Young Rock Chung, MS, Hana Cho, Claude Preudhomme, Omar Abdel-Wahab

Blood (2015) 126 (23): 302.

https://doi.org/10.1182/blood.V126.23.302.302

Published: 2015

Journal Articles

Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA)

Matthieu Duchmann, Thorsten Braun, MD PhD, Uwe Platzbecker, MD PhD, Lionel Adès, MD PhD, Marie Sébert, MD, François Dreyfus, MD, Sophie Park, MD PhD, Norbert Vey, Odile Beyne Rauzy, MD PhD, Stéphane De Botton, MD PhD, Jean-Baptiste Micol, MD, Céline Berthon, MD PhD, Romain Guieze, MD, Jean-Noel M. Bastie, MD PhD, Éric Solary, MD PhD, Pierre Fenaux, MD PhD, Raphaël Itzykson, MD PhD

Blood (2015) 126 (23): 2893.

https://doi.org/10.1182/blood.V126.23.2893.2893

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Christophe Willekens, MD, Angelo Paci, Serge Koscielny, Alice Marceau, Jean-Baptiste Micol, MD, Sophie Broutin, Cyril Quivoron, Véronique Saada, Vianney Poinsignon, Franck Griscelli, Vincent Ribrag, MD, Cristina Castilla-Llorente, Claude Preudhomme, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3833.

https://doi.org/10.1182/blood.V126.23.3833.3833

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Christophe Willekens, MD, Jean-Baptiste Micol, MD, Vianney Poinsignon, Cyril Quivoron, Véronique Saada, Sophie Broutin, Marie Terroir-Cassou-Mounat, David Ghez, Jean-Henri Bourhis, MD PhD, Jacques Bosq, MD, Vincent Ribrag, MD, Angelo Paci, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3835.

https://doi.org/10.1182/blood.V126.23.3835.3835

Published: 2015

Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Benjamin Heath Durham, MD BS, Eli L. Diamond, MD, Julien Haroche, MD PhD, Zhan Yao, PhD, Jing Ma, PhD, Sameer A. Parikh, MD, John Choi, Eunhee Kim, PhD, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, MD, Patrick Campbell, MD PhD, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Aminova Olga, Adriana Heguy, Paul Zappile, Joy Nakitandwe, BSc,MSc,PhD, James Dalton, BS, David W Ellison, MD, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, MD PhD, Phil Stephens, PhD, Vincent A. Miller, MD, Jeffrey Ross, Siraj Ali, Sebastien Héritier, Jean Donadieu, MD PhD, David Solit, MD, David M. Hyman, Jose Baselga, MD PhD, Filip Janku, MDPhD, Barry S. Taylor, PhD, Christopher Y. Park, MD, PhD, Ahmet Dogan, MD PhD, Zahir Amoura, Jean-Francois Emile, Raajit K. Rampal, MD, PhD, Neal Rosen, MD PhD, Tanja A. Gruber, MD PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 481.

https://doi.org/10.1182/blood.V126.23.481.481

Published: 2015

Journal Articles

Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

Stanley Chun-Wei Lee, PhD, Heidi Dvinge, Eunhee Kim, PhD, Hana Cho, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Benjamin Durham, MD PhD, Young Joon Kim, Michael Thomas, Camille Lobry, PhD, Silvia Buonamici, PhD, Peter Smith, Robert K. Bradley, PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 4.

https://doi.org/10.1182/blood.V126.23.4.4

Published: 2015

Journal Articles

A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM

Blood (2015) 126 (23): 2872.

https://doi.org/10.1182/blood.V126.23.2872.2872

Published: 2015

Journal Articles

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Eunhee Kim, PhD, Janine O. Ilagan, PhD, Stanley Lee, PhD, Aravind Ramakrishnan, MD, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Michele E. Murphy, Min-Kyung Kim, BS, Ahmad S. Zebari, Jacob Feala, Silvia Buonamici, PhD, Peter G Smith, PhD, H. Joachim Deeg, MD, Camille Lobry, PhD, Iannis Aifantis, PhD MSC, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 824.

https://doi.org/10.1182/blood.V124.21.824.824

Published: 2014

NARROW

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA)

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only